| Target Price | $17.34 |
| Price | $21.82 |
| Deviation |
20.53%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target MEDNAX, Inc. 2026 .
The average MEDNAX, Inc. target price is $17.34.
This is
20.53%
register free of charge
$19.95
8.57%
register free of charge
$13.13
39.83%
register free of charge
|
|
| A rating was issued by 15 analysts: 9 Analysts recommend MEDNAX, Inc. to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the MEDNAX, Inc. stock has an average upside potential 2026 of
20.53%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.01 | 1.94 |
| 0.92% | 3.52% | |
| EBITDA Margin | 10.73% | 13.07% |
| 10.27% | 21.85% | |
| Net Margin | -4.92% | 8.26% |
| 62.51% | 267.83% |
10 Analysts have issued a sales forecast MEDNAX, Inc. 2025 . The average MEDNAX, Inc. sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an MEDNAX, Inc. EBITDA forecast 2025. The average MEDNAX, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 MEDNAX, Inc. Analysts have issued a net profit forecast 2025. The average MEDNAX, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.19 | 1.85 |
| 63.01% | 255.46% | |
| P/E | 11.82 | |
| EV/Sales | 1.10 |
10 Analysts have issued a MEDNAX, Inc. forecast for earnings per share. The average MEDNAX, Inc. EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| UBS |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Macquarie |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Feb 21 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Feb 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 05 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
May 12 2025 |
|
Locked
Macquarie:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Apr 11 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Feb 21 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Feb 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


